Mihailov MD 1 , Serban M 2 , Badeti R 3 , Popescu B 4 , Tepeneu P 5 , Schramm W 6 1 University Of Medicine and Pharmacy "Victor Babes", Timisoara, Timis, Romania, 2 University of Medicine and Pharmacy, Timisoara, Romania, 3 Children Hospital, Timisoara, Romania, 4 Children Hopsital, Timisoara, Romania, 5 University of Medicine and Pharmacy "Vitctor Babes" Timisoara, Timisoara, Romania, 6 "Ludwig-Maximillians"-University, Munich, GA, Germany In Romanian haemophiliacs, because of limited access to clotting factor concentrates, surgical interventions are made especially in case of severe, life-threatening complications. OBJECTIVE: To realize an economic analysis of orthopedic and surgical interventions. METHODS: In a seven-year period, 37 haemophiliacs (from 224 haemophilia patients registered and treated in Haemophilia Centre Timisoara) underwent 54 surgical and orthopedic interventions. We evaluated: direct medical costs (therapy and hospitalization costs) of these interventions, direct non-medical costs (home-hospital travel costs), indirect costs (morbidity costs; loss of income of family members who forfeit paid employment for haemophiliac home care; average number of days off at school or work), treatment compliance. Data were obtained from patients' medical charts and from questionnaires administered to patients. RESULTS: Therapy costs represented 91.14% of direct medical costs (85.8% in haemophilia A without high-titer inhibitors, 95.34% in haemophilia A with high-titer inhibitors and 92.52% in haemophilia B patients). Direct non-medical costs represented high percents of mean patient and family income. Mean monthly morbidity cost was €97.5 and loss of income of family members who forfeid employment in order to offer home care for haemophilia patients was €115.04/month. Average number of days off at school/work was 72.59/year. CONCLUSIONS: Insufficient resources lead to severe complications in haemophiliacs, which can be life-threatening, requiring costly surgical interventions. In the absence of home therapy programs and of Comprehensive Haemophilia Care Centers, patients have to travel long home-hospital distances to a hospital where they can receive treatment, delaying substitution administration, which is also responsible for complications appearance. Poor social integration of patients has a negative impact on personal income, affecting treatment compliance. It is therefore necessary a better resource allocation for haemophilia treatment, in order to increase direct medical costs and also to offer a better social protection of the patients.
PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS
Van Hulst M 1 , Klok RM 2 , Eschbach ME 3 , Postma MJ 4 1 Groningen University Institute for Drug Exploration / Martini Hospital, Groningen, The Netherlands, 2 University of Groningen, Groningen, The Netherlands, 3 University of Groningen / Groningen Institute for Drug Exploration, Groningen, The Netherlands, 4 University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands OBJECTIVES: For estimating the cost-effectiveness of interventions to avert blood-transfusions it is important to estimate the costs of one unit of allogeneic blood. An example of such an intervention is administration of erythropoietin. Objective of this study was estimating the costs per unit of erythrocytes in The Netherlands from a societal perspective. METHODS: For the estimation of the costs we followed the path from donor to patient. In this path 6 steps were elaborated: donation, production, transport, storage and preparation, administration and the consequences of administration. In these different steps the costconsequences were estimated. RESULTS: Although not all costfactors could yet be identified, the cost-estimate is €240, for a unit of erythrocytes. The indirect costs are responsible for approximately 3% of the unit costs. The production and transport part by the Dutch blood banks is responsible for the majority of the costs. CONCLUSIONS: Internationally cost-estimates vary widely. Cost-estimates for the United States, UK, Sweden and Canada vary from approximately €130 to €930. For The Netherlands we estimated the unit costs for a unit of erythrocytes at €240 from a societal perspective.
PHM7 DIRECT COST OF BETA THALASSEMIA MAJOR: RESUTS FROM THE ITHACA STUDY
Mantovani LG 1 , Ravera S 2 , Scalone L 3 , Cappellini M 4 1 University of Naples, Federico II, Naples, Naples, Italy, 2 Center of Pharmacoeconomics, University of Milan, Milan, Italy, Italy, 3 University of Milan, Milan, Milan, Italy, 4 Congenital Anemia Center, IRCSS Foundation Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan, Milan, Italy OBJECTIVE: Patients with β-Thalassemia Major (TM) require life-long blood transfusions and, to avoid iron overload, Iron Chelation Treatment (ICT), based on 8-12 hour infusions of Deferoxamine (DFO) for 5-7 days/week, and/or Deferiprone (L1) orally administered. ICT regimen often causes low satisfaction and low compliance, with potentially negative consequences on patients' health, wellbeing and costs. Aims: to investigate direct costs of treatment in TM patients. Costs were estimated from the societal perspective, using tariffs or prices applied in 2006. METHODS: The Italian-THAlassemia-Cost-&-Outcomes-Assessment (ITHACA) was a naturalistic multicentre study conducted to evaluate costs, quality of life, compliance and treatment satisfaction in TM patients undergoing ICT. Patients of any age, on ICT for at least 3 years, were sequentially enrolled at 8 Italian Thalassemia Care Centers. Data on direct costs are referred to a retrospective median observational period of 11.7
